However, recent studies demonstrated that IL-6 deficiency does not affect disease outcomes in G93A SOD1 mice modeling ALS [131] and IL-6 blockage with a murine surrogate of tocilizumab revealed deleterious clinical effects in these animals despite a modest anti-inflammatory impact [132]. Here, IL6 is linked to amyotrophic lateral sclerosis.